Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $13.6 million.

  • Adma Biologics' Share-based Compensation rose 58.76% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 102.13%. This contributed to the annual value of $13.6 million for FY2024, which is 120.07% up from last year.
  • According to the latest figures from FY2024, Adma Biologics' Share-based Compensation is $13.6 million, which was up 120.07% from $6.2 million recorded in FY2023.
  • Adma Biologics' 5-year Share-based Compensation high stood at $13.6 million for FY2024, and its period low was $2.9 million during FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $6.2 million (2023), whereas its average is $8.3 million.
  • Data for Adma Biologics' Share-based Compensation shows a peak YoY skyrocketed of 120.07% (in 2024) over the last 5 years.
  • Over the past 5 years, Adma Biologics' Share-based Compensation (Yearly) stood at $2.9 million in 2020, then increased by 22.17% to $3.5 million in 2021, then spiked by 49.51% to $5.2 million in 2022, then grew by 18.64% to $6.2 million in 2023, then surged by 120.07% to $13.6 million in 2024.